The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases
Open accessAbstract
BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in PS1 and PS2 primarily alter APP γ-cleavage, thereby resulting in a decreased Aβ40/42 ratio.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [37]
In the citing paper
“Although causal variants in these genes are typically thought to be inherited in an autosomal dominant fashion, de novo variants in APP, PSEN1, and PSEN2 have also been identified by sequencing in sporadic cases of EOAD that occur with no family history of disease [158, 159].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
A framework for the interpretation of de novo mutation in human disease
Samocha, K. E., Robinson, E. B., Sanders, S. J., Stevens, C., Sabo, A., McGrath, L. M., Kosmicki, J. A., Rehnström, K., Mallick, S., Kirby, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3050 · Cited by 979
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy‐Lahad, E., Wijsman, E. M., Nemens, E. J., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 832
Cited by
Sorted by citations
Items 301–400 of 614
Wei, R., Hu, Q. Z., Lu, Y., & Wang, X. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220613142303 · Cited by 10
Pathophysiology, cellular and molecular mechanisms of large and small vessel diseases
Koueik, J., Wesley, U. V., & Dempsey, R. J. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105499 · Cited by 12
Tracing the GSAP–APP C-99 Interaction Site in the β-Amyloid Pathway Leading to Alzheimer’s Disease
Angira, D., Chikhale, R. V., Mehta, K., Bryce, R. A., & Thiruvenkatam, V. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00332 · Cited by 10
Poniah, P., Rashed, A. A., Jalil, J. A., & Ali, E. Z. (2025) · Genes · doi:10.3390/genes16030345 · Cited by 9
Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omics
Qu, H., Liu, Y., Connolly, J. J., Mentch, F. D., Kao, C., & Hakonarson, H. H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14604 · Cited by 9
Navakkode, S., & Kennedy, B. K. (2025) · Aging Cell · doi:10.1111/acel.70235 · Cited by 10
Hu, Y., Zhang, X., Lian, F., Yang, J. J., & Xu, X. (2021) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.67.234 · Cited by 9
Li, Y., Zhang, J., Ma, B., Yu, W., Xu, M., Luan, W., Yu, Q., Zhang, L., Rong, R., Fu, Y., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124786 · Cited by 10
Rubino, E., Italia, M., Giorgio, E., Boschi, S., Dimartino, P., Pippucci, T., Roveta, F., Cambria, C., Elia, G., Marcinnò, A., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01661-y · Cited by 10
The genetic landscape of early‐onset Alzheimer's disease in China
Qin, W. D., Li, F., Liu, W., Li, Y., Cao, S., Wei, Y., Li, Y., Wang, Y., Wang, Q., & Jia, J. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14486 · Cited by 9
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 10
Patient-derived iPSCs, a reliable in vitro model for the investigation of Alzheimer’s disease
Asiamah, E. A., Guo, R., Kong, D., Feng, B., He, J., Zhang, W., Liu, X., Du, X., Ma, Z., Liu, B., et al. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0065 · Cited by 9
Tarozzi, M. E., Bartoletti‐Stella, A., Dall’Olio, D., Matteuzzi, T., Baiardi, S., Parchi, P., Castellani, G., & Capellari, S. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01173-4 · Cited by 12
Amyloid toxicity in a Drosophila Alzheimer's model is ameliorated by autophagy activation
Tsakiri, E. N., Gumeni, S., Manola, M. S., & Trougakos, I. P. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.017 · Cited by 9
Feole, M., Devoto, V. M. P., Dragišić, N., Arnaiz, C., Bianchelli, J., Texlova, K., Kovačovicova, K. L., Novotný, J., Havas, D., Falzone, T. L., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107137 · Cited by 8
Nguyen, D. L., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103936 · Cited by 9
Ehn, E., Eisfeldt, J., Laffita‐Mesa, J. M., Thonberg, H., Schoumans, J., Portaankorva, A. M., Viitanen, M. H., Lindstrand, A., Nennesmo, I., & Graff, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-86645-0 · Cited by 9
Limitations and Applications of Rodent Models in Tauopathy and Synucleinopathy Research
Szegvari, E., Holec, S. A. M., & Woerman, A. L. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70021 · Cited by 8
Shared early molecular mechanisms revealed in P301S and 5xFAD Alzheimer’s disease mouse models
Suloh, H., Ojha, S. K., Kartawy, M., Hamoudi, W., Tripathi, M. K., Bazbaz, W., Schottlender, N., Ashery, U., Khaliulin, I., & Amal, H. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03321-7 · Cited by 9
Role of Mitochondrial Calcium Dysregulation in Alzheimer’s Disease Pathogenesis
Ebrahimi, R., Hatami, S., Hashempoor, A., Oraee, S., Salarvandian, S., Faramarzi, A., & Esmaeilpour, K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05465-5 · Cited by 9
A Transgenic 5xFAD-M Line of Mice for Dendritic Spine Morphology Analysis in Alzheimer’s Disease
Ilina, A., & Linkova, N. S. (2023) · Brain Sciences · doi:10.3390/brainsci13020307 · Cited by 9
Viruses - a major cause of amyloid deposition in the brain
Fülöp, T., Ramassamy, C., Lévesque, S., Frost, E. H., Laurent, B., Lacombe, G., Khalil, A., Larbi, A., Hirokawa, K., Desroches, M., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2244162 · Cited by 8
Lessons from genetic studies in Alzheimer disease
Nicolas, G. (2024) · Revue Neurologique · doi:10.1016/j.neurol.2023.12.006 · Cited by 9
Self-citationAdvances in nanoprobes for molecular MRI of Alzheimer's disease
Parekh, P. A., Badachhape, A., Tanifum, E. A., Annapragada, A., & Ghaghada, K. B. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1946 · Cited by 9
Mazahir, F., Alam, M. I., & Yadav, A. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102318 · Cited by 9
van der Lee, S. J., Hulsman, M., van Spaendonk, R. M. L., van der Schaar, J., Dijkstra, J. I. R., Tesi, N., van Ruissen, F., Elting, M. W., Reinders, M. J. T., de Rojas, I., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000210273 · Cited by 8
Lee, B. H., Puri, T. A., & Galea, L. A. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00010-7 · Cited by 8
Ayurvedic Herbal Therapies: A Review of Treatment and Management of Dementia
Srivastava, V., Mathur, D., Rout, S., Mishra, B. K., Pannu, V. S., & Anand, A. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220805100008 · Cited by 8
Tiwari, P., Dwivedi, R., Kaushik, M., Tripathi, M., & Dada, R. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02363-2 · Cited by 8
Kotova, M. M., Stewart, A., Grigoryan, A., Shariff, S., Mirzaei, F., Kantawala, B., Dilbaryan, K., de Abreu, M. S., Galstryan, D. S., Cui, J., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70090 · Cited by 7
Tong, X., Tong, Z., Wu, W., Yang, J., Wang, J., Wang, Y., Chen, D., Wang, Y., Zeng, F., Du, Q., et al. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106023 · Cited by 8
Protein quality control systems in neurodegeneration – culprits, mitigators, and solutions?
Ciechanover, A. J., & Livneh, I. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1604076 · Cited by 8
Zhao, R., Sophanpanichkul, P., Chadarevian, J. P., Ding, Y., Dai, H., Nayak, M., Davtyan, H., Blurton-Jones, M. M., & Goldstein, S. A. N. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2509903122 · Cited by 7
Rethinking early Alzheimer’s disease: An impaired internal model updating disorder?
Antonioni, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106790 · Cited by 8
Wang, M., Chen, X., Niu, L., Xu, J., Yu, H., Xu, X., Yang, Q., Xiang, Y., & Le, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14147 · Cited by 7
Are Ischemic Stroke and Alzheimer’s Disease Genetically Consecutive Pathologies?
Filippenkov, I. B., Владимирович, Х. А., Mozgovoy, I. V., Dergunova, L. V., & Limborska, S. A. (2023) · Biomedicines · doi:10.3390/biomedicines11102727 · Cited by 7
Agüero, P., Sainz, M. J., Téllez, R., Lorda, I., Ávila, A., García‐Ribas, G., Rodríguez, P. P., & Gómez‐Tortosa, E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210420 · Cited by 7
proNGF Involvement in the Adult Neurogenesis Dysfunction in Alzheimer’s Disease
Olabiyi, B. F., Fleitas, C., Zammou, B., Ferrer, I., Rampon, C., Egea, J., & EspinetMestre, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910744 · Cited by 7
Mani, R., Sulthana, A. S., Muthusamy, G., & Elangovan, N. (2022) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2317 · Cited by 7
Doğan, M., Eröz, R., Tecellioğlu, M., Gezdirici, A., Çevik, B., & Barış, İ. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220414101251 · Cited by 7
What contribution can genetics make to predict the risk of Alzheimer's disease?
Schramm, C., Wallon, D., Nicolas, G., & Charbonnier, C. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.005 · Cited by 8
Self-citationSheikh, W. G. E., Sleem, B., Kobeissy, F. H., & Bizri, M. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100064 · Cited by 10
Santillán-Morales, V., Rodríguez-Espinosa, N., Muñoz‐Estrada, J., Alarcón-Elizalde, S., Acebes, Á., & Benítez‐King, G. (2024) · Brain Sciences · doi:10.3390/brainsci14010046 · Cited by 8
Wang, D., Scalici, A., Wang, Y., Lin, H., Pitsillides, A., Heard‐Costa, N. L., Cruchaga, C., Ziegemeier, E., Bis, J. C., Fornage, M., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251320375 · Cited by 8
Zhang, H., Zhu, F., Dodge, H. H., Higgins, G. A., Omenn, G. S., Guan, Y., & Initiative, T. A. D. N. (2018) · GigaScience · doi:10.1093/gigascience/giy085 · Cited by 7
Misfolded proteins as a therapeutic target in Alzheimer's disease
Liyanage, S. I., & Weaver, D. F. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.003 · Cited by 8
Neuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRIPreprint
McKay, N. S., Gordon, B. A., Hornbeck, R. C., Jack, C. R., Koeppe, R. A., Flores, S. E., Keefe, S., Hobbs, D. A., Joseph‐Mathurin, N., Wang, Q., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.25.485799 · Cited by 9
Pham, H., Yin, T., & D’Adamio, L. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263546 · Cited by 6
Patwekar, M., Patwekar, F., Khan, S. M., Sharma, R., & Kumar, D. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266295495240415114919 · Cited by 8
Sharma, A., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150047 · Cited by 7
More, S. A., Mundke, R. N., Agrawal, Y. O., Awathale, S. N., Goyal, S. N., Nakhate, K. T., & Rathod, S. S. (2026) · Laboratory Animal Research · doi:10.1186/s42826-026-00278-6 · Cited by 7
Alzheimer's Disease; Mechanism, Mutations, and Applications of Nano-Medicine
Maisam, M., Khan, M. T., Lodhi, M. S., Mou, K., Liu, Z., & Wei, D. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2810258 · Cited by 7
Zebrafish Experimental Animal Models for AD: A Comprehensive Review
Sande, R., Godad, A. P., & Doshi, G. (2024) · Current Clinical Pharmacology · doi:10.2174/0127724328279684240104094257 · Cited by 6
Ko, Y., Ryu, Y., Han, S.-J., Park, H. J., Choi, M., Kim, B. C., Jeong, H., Jang, S., Jo, J., Lee, S., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01040-1 · Cited by 7
Saeed, U., Piracha, Z. Z., Tariq, M. N., Gilani, S. S., Rauf, M. A., Razaq, L., Iftikhar, M. K., Maqsood, A., & Ahsan, S. M. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1422707 · Cited by 7
Loss of the APP regulator RHBDL4 preserves memory in an Alzheimer’s disease mouse model
Penalva, Y. C. M., Paschkowsky, S., Yang, J., Recinto, S. J., Cinkornpumin, J. K., Ruelas, M., Xiao, B., Nitu, A., Kwon, S. Y., Wu, H. Y.-L., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07579-z · Cited by 6
Aathira, N. S., Kaur, A., Kumar, A., Dar, G. M., Nimisha, Sharma, A. K., Bera, P., Mahajan, B., Chatterjee, A., & Saluja, S. S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.021 · Cited by 7
Pharmacogenomic Strategies in Alzheimer’s Disease: An In-Depth Review
Zhou, Y., Peng, S., Wang, H., Cai, X., & Wang, Q. (2024) · Journal of Medical Sciences and Interdisciplinary Research · doi:10.51847/q8jx01pn0m · Cited by 6
A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice
He, R., Liu, J., Huang, C., Liu, J., Cui, H., & Zhao, B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201109091759 · Cited by 6
Very Early-Onset Alzheimer’s Disease in the Third Decade of Life with de novo PSEN1 Mutations
Chen, K.-L., Li, P.-X., Sun, Y.-M., Chen, S.-F., Zuo, C.-T., Wang, J., Dong, Q., Cui, M., & Yu, J.-T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215167 · Cited by 6
Stanciu, G. D., Ababei, D. C., Rusu, R.-N., Bild, V., & Tamba, B.-I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061270 · Cited by 6
Wang, L., Yu, C., Tao, Y., Yang, X., Jiang, Q., Yu, H., & Zhang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1038585 · Cited by 8
Kandeel, M. K., Morsy, M. A., El‐Lateef, H. M. A., Marzok, M., EL-BELTAGI, H. S., Alkhodair, K. M., Albokhadaim, I. F., & Venugopala, K. N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1154607 · Cited by 6
Valdez-Gaxiola, C. A., Maciel‐Cruz, E. J., Hernández‐Peña, R., Dumois‐Petersen, S., Rosales-Leycegui, F., Gallegos‐Arreola, M. P., Moreno-Ortíz, J. M., & Figuera, L. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115687 · Cited by 6
Exploring Heparan Sulfate Proteoglycans as Mediators of Human Mesenchymal Stem Cell Neurogenesis
Petersen, S. I., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-024-01463-8 · Cited by 8
Breaking Barriers in Alzheimer’s Disease: the Role of Advanced Drug Delivery Systems
Shekho, D., Mishra, R., Kamal, R., Bhatia, R., & Awasthi, A. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02923-6 · Cited by 6
Neurodevelopmental origins of neurodegeneration: a lifespan perspective on brain vulnerability
Kopalli, S. R., Vadia, N., Varma, P., Mishra, S., Joshi, N., Bansal, P., Al-Hasnaawei, S., Chauhan, A. S., Jain, H., Nathiya, D., et al. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150134 · Cited by 7
Singh, A. K., & Kundu, T. K. (2026) · ACS Omega · doi:10.1021/acsomega.5c00905 · Cited by 5
Apolipoprotein E4 as a Novel Treatment Target for Alzheimer’s Disease
Jervies, J. L., King, S. P., & Suphioglu, C. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000475 · Cited by 5
Abondio, P., Bruno, F., Bruni, A. C., & Luiselli, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415871 · Cited by 5
Gan, J., Zhou, H., Liu, C., & Fang, L. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06602-5 · Cited by 5
In silico Characterization of Predominant Genes Involved in Early Onset of Alzheimer's Disease
Sachdeva, P., & Ahmad, F. (2021) · The Journal of Neurobehavioral Sciences · doi:10.4103/jnbs.jnbs_34_21 · Cited by 5
Dunn, P. J., Lea, R. A., Maksemous, N., Smith, R. A., Sutherland, H. G. E., Haupt, L. M., & Griffiths, L. R. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03039-3 · Cited by 5
Ceylan, B., Düz, E., & Çakır, T. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03690-4 · Cited by 5
da Silva, S. P., Castro, C. C. M., Rabelo, L. N., Engelberth, R. C. G. J., Fernández‐Calvo, B., & Fiuza, F. P. (2023) · GeroScience · doi:10.1007/s11357-023-00982-4 · Cited by 6
Oxidative Stress in Neurodegenerative Diseases
Alami, M., Fülöp, T., Boumezough, K., Khalil, A., Zerif, E., & Berrougui, H. (2024) · Springer eBooks · doi:10.1007/978-3-031-69962-7_4 · Cited by 6
Salivary Biomarkers and Neurodegenerative Conditions
Thomas, E. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-35784-9_12 · Cited by 5
Genetics of A lzheimer's Disease
Brookes, K. J., & Morgan, K. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0020228.pub2 · Cited by 6
Schultz, S. A., Liu, L., Schultz, A. P., Fitzpatrick, C. D., Levin, R., Bellier, J., Shirzadi, Z., Joseph‐Mathurin, N., Chen, C. D., Benzinger, T. L. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.04.547688 · Cited by 5
Jalali, H., Rahimian, S., Shahsavarian, N., Norouzi, R., Ahmadiyeh, Z., Najafi, H., & Golchin, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123198 · Cited by 4
Tasnády, K. R., Jehoul, R., de Ravé, M. G., Gijbels, M. J., Brône, B., Dewachter, I., Melotte, V., & Boesmans, W. (2025) · Neurogastroenterology & Motility · doi:10.1111/nmo.15016 · Cited by 5
Kaur, J., Sharma, V., Khan, H., Singh, S., & Singh, T. G. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149568 · Cited by 4
A Review Article on Oxidative Stress Markers F2-Isoprostanes and Presenilin-1 in Alzheimer’s Disease
Timalsina, D. R., Abichandani, L. G., & Ambad, R. S. (2025) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_1784_24 · Cited by 4
Lanjewar, D., Katariya, R., Kale, V., Taksande, B. G., Umekar, M. J., & Vinchurney, M. D. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102547 · Cited by 4
Application of computational methods in the drug discovery and development of Alzheimer's disease
Zhang, Q., Gong, X., Liu, H., & Yao, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.038 · Cited by 5
Recent Advances and Future Directions in Alzheimer’s Disease Genetic Research
Stancheva, M., Toncheva, D. I., & Karachanak-Yankova, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167819 · Cited by 4
Genetic and epigenetic drivers of neurodegenerative disorders
Roy, K., Syed, M., Narad, P., & Sengupta, A. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.002 · Cited by 5
Bridging the gap in the management of Alzheimer's disease using fecal microbiota transplantation
Bashir, B., Gulati, M., Vishwas, S., Hussain, M. S., Gupta, G., Kumar, P., Negi, P., Mittal, N., Dua, K., & Singh, S. K. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.104052 · Cited by 5
The roles of biomarkers in Alzheimer's disease clinical trials
Cummings, J. L., Sharma, S., DeAndrea, G., Osse, A. M. L., & Ortiz, A. A. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00811 · Cited by 4
Zohud, O., Lone, I. M., Midlej, K., & Iraqi, F. A. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70131 · Cited by 4
Won, S., Kim, Y., & Jeong, B. (2021) · Medicina · doi:10.3390/medicina58010055 · Cited by 4
Zhai, T., Krass, E., Zhang, F., & Huang, Z. J. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1188430 · Cited by 6
Presenilin‐2 knock‐In mice show severe depressive behavior via DVL3 downregulation
Yoo, S. S., Lee, D. W., Ham, H. J., Yeo, I. J., Chang, J. Y., Yun, J., Son, D. J., Han, S., & Hong, J. T. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14370 · Cited by 5
Uh, K., Monarch, K., Reese, E. D., Rodriguez, K., Yoon, J. D., Spate, L. D., Samuel, M., Koh, S., Chen, P. R., Jarome, T. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231297 · Cited by 4
Bulgart, H. R., Perez, M. A. L., Tucker, A., Giarrano, G. N., Banford, K. K., Miller, O., Bonser, S. W. G., Wold, L. E., Scharre, D. W., & Weisleder, N. L. (2024) · The FASEB Journal · doi:10.1096/fj.202401731rr · Cited by 4
Shome, A., Jha, K. T., Chahat, Chawla, V., & Chawla, P. A. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273315191241002115155 · Cited by 4
Chang, Z., Wang, Z., Luo, L., Xie, Z., Yue, C., Bian, X., Yang, H., & Wang, P. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1423892 · Cited by 4
Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse
Plucińska, K., Crouch, B., Yeap, J., Stoppelkamp, S., Riedel, G., & Platt, B. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180336 · Cited by 4
Huang, J., Lu, D., & Meng, G. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.571609 · Cited by 4
Precise regulation of presenilin expression is required for sea urchin early development
Bronchain, O. J., Philippe-Caraty, L., Anquetil, V., & Ciapa, B. (2021) · Journal of Cell Science · doi:10.1242/jcs.258382 · Cited by 4
Metadata
- Authors
- Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., Rouaud, O., Ceccaldi, M., Félician, O., Godefroy, O., Formaglio, M., Croisile, B., Auriacombe, S., Chamard, L., Vincent, J.-L., Sauvée, M., Marelli-Tosi, C., Gabelle, A., Ozsancak, C., Pariente, J., Paquet, C., Hannequin, D., Campion, D., & collaborators of the CNR-MAJ project
- Affiliations
- Inserm (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Centre National de la Recherche Scientifique (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Corresponding author
- Campion, Dominique
- ORCID
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-03-28
- Volume
- 14
- Issue
- 3
- Pages
- e1002270
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC5370101
- OpenAlex
- W2600872530
- Cited by
- 616
- References
- 44
- Citations by year
- 2026: 58 · 2025: 102 · 2024: 94 · 2023: 75 · 2022: 79 · 2021: 64 · 2020: 58 · 2019: 41 · 2018: 34 · 2017: 9
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
- Funders
- Clinical Research Hospital Program from the French Ministry of Health (GMAJ 2008/067)
- French Ministry of Health (CNR-MAJ)
- European Union (JPND PERADES, ANR-13-JPRF-0001-04)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- early-onset Alzheimer's disease, APP mutations, PSEN1 mutations, PSEN2 mutations, presenilin, amyloid precursor protein, novel mutations, de novo mutations, sporadic Alzheimer's disease, familial Alzheimer's disease, genetic screening, variant interpretation, cerebrospinal fluid biomarkers, total tau, phosphorylated tau, amyloid-beta 42, genetic counseling, mutation carriers
- MeSH terms
- Adult, Alzheimer Disease, Female, France, Genetic Testing, Humans, Male, Middle Aged, Mutation, Amyloid beta-Protein Precursor, Age of Onset, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
